Samsung partners with Alcedis to use wearable tech in clinical trials
Samsung partners with Alcedis to use wearable tech in clinical trials
Updated at: June 24, 2026 at 09:00 AM
On June 24, 2026, Samsung Electronics unveiled a strategic partnership with Alcedis, a German clinical research organization, to revolutionize how new drugs are developed.
By integrating Samsung’s advanced wearable technology into clinical trials, the companies aim to transition research away from hospital-centric models toward decentralized clinical trials (DCT).
The initiative focuses on using data from the Galaxy Watch to provide continuous, real-world health insights.
Samsung provides the hardware and sensor infrastructure, including sophisticated biosensors like Bioelectrical Impedance Analysis (BIA) and Electrodermal Activity (EDA), alongside software for monitoring conditions such as sleep apnea and atrial fibrillation.
By shifting to this data-driven approach, researchers can reduce the burden of frequent hospital visits for patients, improve the reliability of data, and ultimately accelerate the pace of medical innovation.
This partnership marks a significant step toward a more efficient, patient-centric future for clinical research and healthcare.
